🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being described as a "significant breakthrough" in the effort against drug-resistant strains of the bacteria, according to scientists.

An International Health Concern

Gonorrhoea infections are increasing globally, with estimates suggesting in excess of 82 million new cases each year. Notably increased rates are seen in the African continent and nations within the World Health Organization's Western Pacific region, which includes Mongolia and China to New Zealand. In England, cases have reached a historical peak, while figures across Europe in 2023 were three times higher compared to figures for 2014.

“The clearance of novel therapies for gonorrhoea is an significant and necessary advancement in the reality of increasing worldwide cases, increasing antimicrobial resistance and the extremely scarce treatment choices presently on offer.”

Health officials are particularly alarmed about the increase in antibiotic-resistant strains. The World Health Organization has designated it as a "high-priority threat". A tracking program found that resistance to standard treatments like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Drugs Gain Authorization

Zoliflodacin, alternatively called a brand name, was authorized by the American regulatory agency in mid-December for combating gonorrhoea. This disease can lead to significant complications, including infertility. Experts anticipate that focused deployment of this new drug will help slow the emergence of superbugs.

Gepotidacin, originating from the drugmaker GSK, was also approved in concurrent days. This drug, which is also used to treat urinary tract infections, was shown in trials to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Development Model

This new treatment emerged from a unique collaborative effort for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the drug firm Innoviva to bring it to fruition.

“This milestone signifies a huge turning point in the treatment of multidrug-resistant gonorrhoea, which until now has been outpacing antibiotic development.”

Clinical Trial Data and Global Access

Based on data published in a prominent scientific publication, zoliflodacin successfully treated the vast majority of uncomplicated infections. This establishes an similar efficacy with the current standard treatment, which combines two antibiotics. The study included hundreds of volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, GARDP has the authority to make available and distribute the drug in many low-income and middle-income countries.

Doctors on the front lines have expressed positive views. Access to a easy-to-administer therapy of this kind is described as a "revolutionary step" for managing the epidemic. This is viewed as essential to reduce the burden of the infection for patients and to prevent the spread of highly drug-resistant gonorrhoea globally.